Global Neuromodulation Devices Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

By Product;

Spinal Cord Stimulators, and Deep Brain Stimulators

By Technology;

Internal Neuromodulation, and External Neuromodulation (Non-Invasive)

By Application;

Parkinson's Disease, Epilepsy, Tremor, Depression, Migraine, Failed Back Syndrome, Chronic Pain, Urine Incontinence, Fecal Incontinence, Treatment Resistant Depression, Spinal Cord Injury, Obesity, Ischemia, Gastroparesis, and Others

By Biomaterial;

Metallic Biomaterials, Polymeric Biomaterials, and Ceramic Biomaterials

By Geography;

North America, Europe, Asia Pacific, Middle East & Africa, and Latin America - Report Timeline (2021 - 2031)
Report ID: Rn114575583 Published Date: May, 2025 Updated Date: June, 2025

Neuromodulation Devices Market Overview

Neuromodulation Devices Market (USD Million)

Neuromodulation Devices Market was valued at USD 13,010.72 million in the year 2024. The size of this market is expected to increase to USD 33,487.10 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 14.5%.


Global Neuromodulation Devices Market Growth, Share, Size, Trends and Forecast

*Market size in USD million

CAGR 14.5 %


Study Period2025 - 2031
Base Year2024
CAGR (%)14.5 %
Market Size (2024)USD 13,010.72 Million
Market Size (2031)USD 33,487.10 Million
Market ConcentrationLow
Report Pages327
13,010.72
2024
33,487.10
2031

Major Players

  • Medtronic Plc
  • Boston Scientific Corporation
  • Cyberonics Inc
  • Biocontrol Medical
  • Nevro Corporation
  • Abbott Laboratories
  • Neuronetics Inc
  • Neuropace Inc
  • Synapse Biomedical Inc
  • Neurosigma Inc

Market Concentration

Consolidated - Market dominated by 1 - 5 major players

Global Neuromodulation Devices Market

Fragmented - Highly competitive market without dominant players


The Neuromodulation Devices Market continues to grow steadily, driven by the shift toward targeted, non-pharmacological treatment methods for complex neurological conditions. These devices deliver electrical impulses to regulate nerve activity, with over 55% of their usage focused on managing chronic pain. Their ability to offer precision in therapeutic interventions is fueling adoption in both clinical and outpatient settings.

Technological Advancements Fueling Market Growth
Continuous innovation in device design and delivery systems is accelerating market development. Battery-less implants and feedback-enabled systems now represent close to 25% of all recent product introductions. These improvements are enhancing usability and precision, contributing to better patient compliance and long-term outcomes.

Regulatory Support and Insurance Integration
Favorable clinical policies and expanded reimbursement programs are making neuromodulation devices more widely available. Nearly 40% of treatments involving these devices are now integrated into formal insurance structures. This accessibility is enabling broader implementation in diverse treatment protocols across neurological and psychiatric care.

Expanding Research and Technology Ecosystem
The future of the neuromodulation market is being shaped by robust research funding and integration of intelligent digital tools. Over 35% of neurotechnology research is currently directed at device-led interventions. The blending of AI with neuromodulation platforms is enhancing therapy monitoring, signaling strong growth prospects for the industry.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Product
    2. Market Snapshot, By Technology
    3. Market Snapshot, By Application
    4. Market Snapshot, By Biomaterial
    5. Market Snapshot, By Region
  4. Neuromodulation Devices Market Dynamics
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Increasing Prevalence Of Chronic Neurological Conditions
        2. Advancements In Minimally Invasive Neurostimulation Technologies
        3. Growing Demand For Pain Management Alternatives
        4. Rising Geriatric Population With Neuro Disorders
      2. Restraints
        1. High Cost Of Neuromodulation Implant Procedures
        2. Limited Awareness In Developing Healthcare Systems
        3. Device Malfunction Risks And Patient Safety Concerns
        4. Complex Reimbursement And Regulatory Approval Pathways
      3. Opportunities
        1. Emergence Of Closed-Loop Neuromodulation Systems
        2. Adoption In Psychiatric And Behavioral Disorders
        3. Expansion Of Home-Based Neuromodulation Applications
        4. Integration With AI For Precision Treatment
    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry
  5. Market Segmentation
    1. Neuromodulation Devices Market, By Product, 2021 - 2031 (USD Million)
      1. Spinal Cord Stimulators
      2. Deep Brain Stimulators
    2. Neuromodulation Devices Market, By Technology, 2021 - 2031 (USD Million)
      1. Internal Neuromodulation

      2. External Neuromodulation (Non-Invasive)

    3. Neuromodulation Devices Market, By Application, 2021 - 2031 (USD Million)
      1. Parkinson’s Disease
      2. Epilepsy
      3. Tremor
      4. Depression
      5. Migraine
      6. Failed Back Syndrome
      7. Chronic Pain
      8. Urine Incontinence
      9. Fecal Incontinence
      10. Treatment Resistant Depression
      11. Spinal Cord Injury
      12. Obesity
      13. Ischemia
      14. Gastroparesis
      15. Others
    4. Neuromodulation Devices Market, By Biomaterial, 2021 - 2031 (USD Million)
      1. Metallic Biomaterials
      2. Polymeric Biomaterials
      3. Ceramic Biomaterials
    5. Neuromodulation Devices Market, By Geography, 2021 - 2031 (USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Nordic
        7. Benelux
        8. Rest of Europe
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia & New Zealand
        5. South Korea
        6. ASEAN (Association of South East Asian Countries)
        7. Rest of Asia Pacific
      4. Middle East & Africa
        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
      5. Latin America
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
  6. Competitive Landscape
    1. Company Profiles
      1. Medtronic Plc
      2. Boston Scientific Corporation
      3. Cyberonics Inc
      4. Biocontrol Medical
      5. Nevro Corporation
      6. Abbott Laboratories
      7. Neuronetics Inc
      8. Neuropace Inc
      9. Synapse Biomedical Inc
      10. Neurosigma Inc
  7. Analyst Views
  8. Future Outlook of the Market